Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

PT-141 / Bremelanotide.

Research draft

Bremelanotide, also called PT-141, is a melanocortin receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Bremelanotide, also called PT-141, is a melanocortin receptor agonist.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It acts through central melanocortin signalling relevant to sexual desire.

Human research

Controlled clinical development supports a specific sexual-desire indication; early male studies are a separate evidence context.

Preclinical & other research

Receptor experiments established its melanocortin activity.

Safety & unknowns

Nausea, transient blood-pressure increases and pigmentation changes are important. Contraindications depend on the approved label.

Regulatory status

Vyleesi is a US prescription product for a defined group of premenopausal women; it is not broadly approved for every sexual complaint.

Reported use & evidence

Research profile draft

The supplied PT-141 / Bremelanotide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds